Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Compugen Establishes SAB to Guide Pipeline Program Development

Published: Tuesday, August 27, 2013
Last Updated: Tuesday, August 27, 2013
Bookmark and Share
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.

Compugen Ltd. has announced the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company’s activities in the fields of immunology and oncology, including its early stage pipeline of therapeutic proteins and monoclonal antibodies.

The members of Compugen's SAB include four renowned translational scientists and clinicians in oncology and immunology.

Listed in alphabetical order, the members are: Charles G. Drake, MD, PhD, Associate Professor of Oncology, Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain B. McInnes, MD, PhD, Director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow; Antoni Ribas, MD, PhD, Professor at the Department of Medicine, Hematology/Oncology, University of California Los Angeles; and Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, Prostate Cancer Foundation.

Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are delighted to welcome this prestigious group of scientists to our Scientific Advisory Board for oncology and immunology, two therapeutic fields with substantial unmet medical needs and the primary fields of focus for Compugen. We very much appreciate their willingness and enthusiasm to collaborate with us as members of our SAB, which we view as further recognition of our growing presence in these important therapeutic areas.”

Dr. Cohen-Dayag continued, “Recently we announced the signing of our first agreement covering product candidates identified in our initial focused discovery program based on our unique predictive discovery infrastructure. This specific discovery effort was focused on immune checkpoint proteins, and this first agreement, with Bayer HealthCare, covered the development and commercialization of antibody therapeutics against two novel oncology targets for cancer immunotherapy.”

Dr. Cohen-Dayag concluded, “We are confident that the knowledge and experience of our newly formed SAB, which includes well-recognized world experts in the field of immune checkpoint proteins, will prove invaluable as we continue our development and commercialization efforts for our current product candidates, undertake additional focused discovery programs, and further enhance our predictive discovery infrastructure through deeper insights into the underlying science.”

Compugen’s Scientific Advisory Board Members:

Charles G. Drake, MD, PhD
Dr. Drake specializes in cancer immunotherapies, focusing on immune checkpoints, and cancer vaccines. He has significant experience conducting clinical trials involving these therapies. He is Co-Director of the Multi-disciplinary Prostate Cancer Clinic at Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, and is an Associate Professor, Medical Oncology, Immunology, and Urology. Dr. Drake is also a member of the Prostate Cancer Foundation Scientific Advisory Board. Dr. Drake received his PhD in Immunology from the National Jewish Center for Immunology and his MD from the University of Colorado Health Sciences Center in Denver, Colorado.

Iain B. McInnes, FRCP, PhD
Prof. McInnes’ major area of interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He is Muirhead Chair of Medicine and Director of Institute of Infection, Immunity and Inflammation at the University of Glasgow. He oversees a translational science program and is involved with an extensive clinical trials facility performing studies of novel biologic agents in inflammatory arthritis. He has served as Principal Investigator for numerous clinical studies in drug development programs. Prof. McInnes studied medicine at the University of Glasgow, and trained in PhD and postdoctoral studies at the National Institutes of Health in Bethesda, Maryland.

Antoni Ribas, MD, PhD
Prof. Ribas holds positions in Hematology/Oncology and Surgical Oncology at the University of California, Los Angeles (UCLA). He conducts laboratory and clinical research on novel strategies for immunotherapy of cancer, focusing on malignant melanoma, and has served as Principal Investigator for clinical studies in drug development programs. He is the Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG (Southwest Oncology Group). Prof. Ribas is also a permanent committee member of the National Cancer Institute (NCI) grant review panels and an elected member of the American Society of Clinical Investigation (ASCI). He studied medicine at the University of Barcelona, Spain, and has undergone postdoctoral training at the Sidney Kimmel Cancer Center in San Diego and at UCLA.

Howard R. Soule, PhD
Dr. Soule is a world leader in the identification and development of new drugs for prostate cancer. Dr. Soule is the Executive Vice President and Chief Science Officer at the Prostate Cancer Foundation, and Senior Fellow at the Milken Institute. He coordinates global academic, government and biopharmaceutical sector research activity and is responsible for the implementation of Prostate Cancer Foundation global research strategies. Dr. Soule received his PhD from Baylor College of Medicine in virology and epidemiology, and was a postdoctoral fellow in immunology and vascular biology at the Scripps Research Institute. Dr. Soule has substantial R&D and business development experience in the biopharmaceutical and diagnostics industries.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Obtains Rights to Use Biological Systems and Materials
Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs.
Wednesday, April 15, 2015
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
New facilities double available space for corporate offices and research and discovery in Israel.
Wednesday, March 25, 2015
Compugen Expands and Strengthens Business Development Team
Felix Karim, PhD, joins Company as Vice President Corporate & Business Development.
Tuesday, March 10, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Announces Presentations of Results for CGEN-15001
Data indicating novel mechanism of action for CGEN-15001 in maintaining long-term therapeutic effect presented at International Conference on Immune Tolerance in Amsterdam.
Wednesday, October 01, 2014
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Thursday, December 12, 2013
Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.
Friday, October 11, 2013
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Announces Collaboration and License Agreement with Bayer
Compugen to hold 2nd Quarter Conference Call August 7, 2013.
Tuesday, August 06, 2013
Compugen Reports First Quarter 2013 Financial Results
CEO to update Company status in quarterly conference call.
Monday, April 29, 2013
Compugen Discloses Focused Target Discovery Program for ADC Cancer Therapy
Initial discoveries from new program anticipated before year-end.
Tuesday, April 09, 2013
Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary
Keddem's unique technology platform focuses on small molecule drug discovery.
Thursday, March 21, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!